CDH17-targeted CAR-T cells for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific protein called CDH17 (tested in a lab).
- You must be between 18 and 75 years old.
- Standard cancer treatments have stopped working or are not right for you.
- You should have at least one measurable tumor outside the brain (on scans).
- You need to be generally active (able to do light work or daily tasks) without serious heart, lung, kidney, or infection problems.
- You cannot be pregnant, breastfeeding, or planning to have a child within 2 years of treatment.
- No active brain metastases or other uncontrolled major health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called anti-CDH17 CAR-T cells for people with advanced solid tumors that are CDH17-positive. The therapy uses your own immune cells, modified to target and destroy cancer cells, and aims to help when other treatments have stopped working.
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Hear when a new CDH17-positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.